REFERENCES 
1 . Estimates of HIV prevalence and projected AIDS cases: 
summary of a workshop October 31 - November 1 , 1 989. 
MMWR 39:110-119 (1990). 
2. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection 
and isolation of cytopathic retrovirus (HTLV-III) from patients with 
AIDS and at risk for AIDS. Science 224:500 (1984). 
3. Barre-Sinoussi F, Nugeyre M, Dauguet C, et al. Isolation of a T- 
lymphotropic retrovirus from a patients at risk for acquired 
immune deficiency syndrome. Science 220:868 (1983). 
4. Popovic M, Samgadharon MG, Read E, Gallo RC. Detection, 
isolation, and continuous production of cytopathic retrovirus 
(HTLV-III) from patients with AIDS and pre-AIDS. Science 
224:497 (1984). 
5. Curran JW, Jaffe HW, Hardy AM. Epidemiology of HIV infection 
and AIDS in the United States. Science 239:610 (1988). 
6. Mann J, Chin J, Piot P, Ouinn T. The International Epidemiology 
of AIDS. Scientific American 259:82-89 (1988), 
7. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of 
azidothymidine in the treatment of patients with AIDS and AIDS- 
related complex. N Engl J Med 317:185-191 (1987). 
8. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in 
asymptomatic human immunodeficiency virus infection. N Engl 
J Med 322:941-949 (1990). 
9. Fischl MA, Richman DD, Hansen N, et al. The safety and 
efficacy of zidovudine (AZT) in the treatment of subjects with 
mildly symptomatic human immunodeficiency virus type 1 (HIV) 
infection. Ann Intern Med 112:727-737 (1990). 
10. Friedland GH. Early treatment for HIV: the time has come. N 
Engl J Med 322:1000-1002 (1990). 
11. Ruedy J, Schechter M, Mantaner JSG. Zidovudine for early 
human immunodeficiency virus (HIV) infection: Who, when, and 
how? Ann Intern Med 112:721-723 (1990). 
Recombinant DNA Research, Volume 16 
[311] 
